Br[CH2:2][C:3]([CH:5]1[CH2:8][N:7]([C:9]([O:11][C:12]([CH3:15])([CH3:14])[CH3:13])=[O:10])[CH2:6]1)=O.[Cl:16][C:17]1[N:22]=[N:21][C:20]([NH2:23])=[C:19]([N:24]2[CH2:29][CH2:28][O:27][CH2:26][CH2:25]2)[CH:18]=1>CN(C=O)C>[Cl:16][C:17]1[CH:18]=[C:19]([N:24]2[CH2:29][CH2:28][O:27][CH2:26][CH2:25]2)[C:20]2[N:21]([CH:2]=[C:3]([CH:5]3[CH2:8][N:7]([C:9]([O:11][C:12]([CH3:15])([CH3:14])[CH3:13])=[O:10])[CH2:6]3)[N:23]=2)[N:22]=1A solution of tert-butyl 3-(2-bromoacetyl)azetidine-1-carboxylate (207 mg, 0.744 mmol) in DMF (1 mL) was added to a solution of compound 19a (99.8 mg, 0.465 mmol) and Na2HPO4 (165 mg, 2.50 mmol) in DMF (20 mL). The resulting mixture was stirred at rt overnight. The reaction mixture was concentrated in vacuo and the residue obtained was purified by normal phase column chromatography on silica gel (0-100% EtOAc/heptane) to obtain compound 19b. Mass Spectrum (LCMS, ESI pos.): Calcd. for C19H25ClN4O3: 393.2 (M+H). found: 393.3.